Cancer of Unknown Primary Site Active Not Recruiting Phase 2 Trials for Pemigatinib (DB15102)
Indication | Status | Phase |
---|---|---|
DBCOND0089665 (Cancer of Unknown Primary Site) | Active Not Recruiting | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | Treatment |
|